Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073021 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 386
- Enrollment target
NCT00073021 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 386 participants.
The verdict
NCT00073021, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 386 participants
- Enrollment target
Study Summary
This study is a prospective clinical study to evaluate the safety and efficacy of two different doses of Asacol for the treatment of moderately active ulcerative colitis. In addition, a new tablet formulation will be evaluated at one of the two doses.
Interventions
- DRUG Asacol 800 mg (mesalamine)
- DRUG Asacol 400 mg (mesalamine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2000-09 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073021
The ClinicalTrials.gov registry entry for NCT00073021 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Asacol 800 mg (mesalamine) is the first listed.
NCT00073021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073021 about?
NCT00073021 is a clinical study titled "Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis". This study is a prospective clinical study to evaluate the safety and efficacy of two different doses of Asacol for the treatment of moderately active ulcerative colitis. In addition, a new tablet formulation will be evaluated at one of the two doses.
What is the current status of trial NCT00073021?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 386 participants. The study started on 2000-09. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00073021?
The interventions under investigation include: Asacol 800 mg (mesalamine) (DRUG), Asacol 400 mg (mesalamine) (DRUG).
Who is sponsoring clinical trial NCT00073021?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.